首页> 美国卫生研究院文献>other >Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma: Challenges for Personalized Therapy
【2h】

Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma: Challenges for Personalized Therapy

机译:横纹肌样肾细​​胞癌的肿瘤内形态和分子异质性:个性化治疗的挑战。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rhabdoid histology in clear cell renal cell carcinoma is associated with a poor prognosis. The prognosis of patients with clear cell renal cell carcinoma may also be influenced by molecular alterations. The aim of this study was to evaluate the association between histologic features and salient molecular changes in rhabdoid clear cell renal cell carcinoma. We macrodissected the rhabdoid and clear cell epithelioid components from 12 cases of rhabdoid clear cell renal cell carcinoma. We assessed cancer related mutations from 8 cases using a clinical next generation exome sequencing platform. The transcriptome of rhabdoid clear cell renal cell carcinoma (n=8) and non-rhabdoid clear cell renal cell carcinoma (n=37) was assessed by RNA-seq and gene expression microarray. VHL (63%) showed identical mutations in all regions from the same tumor. BAP1 (38%) and PBRM1 (13%) mutations were identified in the rhabdoid but not the epithelioid component and were mutually exclusive in 3/3 cases and 1 case, respectively. SETD2 (63%) mutations were discordant between different histologic regions in 2/5 cases, with mutations called only in the epithelioid and rhabdoid components, respectively. The transcriptome of rhabdoid clear cell renal cell carcinoma was distinct from advanced stage and high grade clear cell renal cell carcinoma. The diverse histologic components of rhabdoid clear cell renal cell carcinoma, however, showed a similar transcriptomic program, including a similar prognostic gene expression signature. Rhabdoid clear cell renal cell carcinoma is transcriptomically distinct and shows a high rate of SETD2 and BAP1 mutations and a low rate of PBRM1 mutations. Driver mutations in clear cell renal cell carcinoma are often discordant across different morphologic regions whereas the gene expression program is relatively stable. Molecular profiling of clear cell renal cell carcinoma may improve by assessing for gene expression and sampling tumor foci from different histologic regions.
机译:透明细胞肾细胞癌中的横纹肌组织学与不良预后有关。透明细胞肾细胞癌患者的预后也可能受到分子改变的影响。这项研究的目的是评估组织学特征和横纹肌透明细胞肾细胞癌的显着分子变化之间的关联。我们从12例横纹肌透明细胞肾细胞癌中宏观剖析了横纹肌和透明细胞上皮样成分。我们使用临床下一代外显子组测序平台评估了8例癌症相关的突变。通过RNA-seq和基因表达微阵列评估了横纹肌透明细胞肾细胞癌(n = 8)和非横纹肌透明细胞肾细胞癌(n = 37)的转录组。 VHL(63%)在同一肿瘤的所有区域均显示出相同的突变。在横纹肌中发现了BAP1(38%)和PBRM1(13%)突变,但在上皮样成分中却没有,并且在3/3例和1例中是互斥的。 SETD2(63%)突变在2/5例的不同组织学区域之间不一致,仅在上皮样和横纹肌成分中分别称为突变。横纹肌透明细胞肾细胞癌的转录组不同于晚期和高级别透明细胞肾细胞癌。然而,横纹肌透明细胞肾细胞癌的多种组织学成分显示了相似的转录组程序,包括相似的预后基因表达特征。横纹肌透明细胞肾细胞癌在转录组上是截然不同的,并且显示出较高的SETD2和BAP1突变率和较低的PBRM1突变率。透明细胞肾细胞癌中的驱动子突变通常在不同的形态学区域不一致,而基因表达程序相对稳定。透明细胞肾细胞癌的分子谱分析可通过评估基因表达并从不同组织学区域取样肿瘤灶来改善。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号